“…63 In recent years, different ligands have been used to construct PDT-based diagnostic and treatment systems with active targeting moieties, including peptides (RGD 64 and epidermal growth factor 65 ), proteins (vascular endothelial growth factor, 66 transferrin 67 and antibodies 68 ), aptamers, 69,70 vitamins (biotin 71 and folic acid 72,73 ) and carbohydrates. 74 However, in most of the recent PDT systems, the PS and the targeted ligand are combined by physical adsorption or encapsulation, which pose the risk of dissociation of PS from the targeted ligand in plasma, thereby reducing the targeting capacity of the PDT system and resulting in weakened therapeutic effect, as well as increased toxicity to normal tissues.…”